Loading...
•
Dec 31, 2020
Jazz Pharmaceuticals Q4 2020 Earnings Report
Jazz Pharmaceuticals reported Q4 2020 earnings with total revenues increasing by 14% and launched Xywav in the U.S.
Key Takeaways
Jazz Pharmaceuticals announced its Q4 2020 financial results, with total revenues increasing by 14% compared to the same period in 2019. The company highlighted the successful U.S. launches of Zepzelca and Xywav and provided full year 2021 total revenue guidance of $2.55 Billion to $2.70 Billion.
Total revenues increased 14% in the fourth quarter of 2020 compared to the same period in 2019.
Neuroscience net product sales in the fourth quarter of 2020 increased 6% compared to the same period in 2019, driven by the launch of Xywav.
Oncology net product sales in the fourth quarter of 2020 increased 46% compared to the same period in 2019, led by Zepzelca net product sales.
The company expects 2021 to be another catalyst-rich year as they focus on their ambitious set of objectives.
Jazz Pharmaceuticals
Jazz Pharmaceuticals
Jazz Pharmaceuticals Revenue by Segment
Revenue by Segment
Other Revenue
CapyFin.com Forward Guidance
Jazz Pharmaceuticals provided full year 2021 financial guidance on a standalone basis and does not reflect the impact of the proposed acquisition of GW Pharmaceuticals. They plan to provide updated guidance following the close of the planned transaction.
Positive Outlook
- Revenues $2,550 - $2,700 million
- Total net product sales $2,540 - $2,685 million
- Neuroscience $1,785 - $1,885 million
- Oncology $715 - $835 million
- Net income per diluted share $8.30 - $10.45
Challenges Ahead
- SG&A expenses $1,032 - $1,100 million
- SG&A expenses as % of total revenues 38% - 43%
- R&D Expenses $365 - $410 million
- R&D expenses as % of total revenues 14% - 16%
- Effective tax rate 18% - 20%